Executive Summary The GLP-1 receptor agonist (GLP-1 RA) drug class originally developed for type 2 diabetes but now a leading therapy for chronic weight management has experienced explosive demand growth that is straining global production capabilities
Yet, their ultimate impact will be shaped not only by biological efficacy, but also by the evolving societal and professional discourse surrounding obesity, the medicalization of weight, and the persistent challenge of stigma
Tzimtzimis, O
The cost of GLP-1 drugs, which treat obesity and diabetes, have been a driver of the increased costs for PEIA, Cunningham said
This approach helps more patients stay on the treatment, experience the full health benefits of these medications, and make real progress in reducing obesity and overweight rates in the United States. Noom reports strong early outcomes with microdosing strategy This gradual approach referenced by Egler is Nooms low and slow titration approach with microdoses, which are considered fractions of the standard medication doses, 25% or less
Settlement Agreements and Potential Challenges to Fully Resolving Employment Disputes," Dallas Bar Association, Labor and Employment Section, Dallas, TX (Download presentation here)